within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H02A_CorticosteroidsForSystemicUsePlain.H02AB18_Vamorolone;

model Vamorolone
  extends Pharmacolibrary.Drugs.ATC.H.H02AB18
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.63,
    Cl             = 2.702777777777778e-06,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,
    adminCount     = 1,
    Vd             = 0.00114,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01175,
    Tlag           = 17.4  
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Vamorolone</td></tr><tr><td>ATC code:</td><td>H02AB18</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>6</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.14</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.139</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Vamorolone is a synthetic corticosteroid designed to retain anti-inflammatory efficacy similar to glucocorticoids such as prednisolone, while reducing the side effects associated with standard corticosteroids. It is being developed primarily for use in Duchenne muscular dystrophy (DMD) and other inflammatory disorders. As of 2024, vamorolone has received approval for DMD in several countries and remains under investigation for additional indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following single oral dosing; population PK modeling.</p><h4>References</h4><ol><li><p>Mavroudis, PD, et al., &amp; Jusko, WJ (2019). Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. <i>Journal of clinical pharmacology</i> 59(7) 979â€“988. DOI:<a href=\"https://doi.org/10.1002/jcph.1388\">10.1002/jcph.1388</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30742306/\">https://pubmed.ncbi.nlm.nih.gov/30742306</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Vamorolone;
